Some of the most important technological advances happen through convergence rather than a single discovery. Pioneers sometimes see developments around them from a different perspective. Whether by design or lucky accident, when motivated people are in the right place at the right time, they can draw from and build on developments and trends in multiple fields, apply their own expertise, make new discoveries and integrate what they learn to create new products, services and technologies that change the world. In healthcare, the new therapeutic field of bioelectronic medicine also draws on a wave of convergence, leveraging: • Increasing understanding of immunology and neuroscience • Experience learned in the last few decades implanting active medical devices • Awareness of the side effects of pharmaceuticals • The new challenges in healthcare economics

Like Comment

SetPoint Medical White Paper: The Evolution of Bioelectronic Medicine 

Go to the profile of SetPoint Medical

SetPoint Medical

SetPoint Medical is a privately held biomedical technology company dedicated to treating patients with debilitating inflammatory diseases using bioelectronic therapy. SetPoint’s approach is intended to offer patients and providers an alternative for the treatment of rheumatoid arthritis (RA) and other chronic inflammatory diseases with less risk and cost than drug therapy. SetPoint is developing a novel bioelectronic medicine platform that stimulates the vagus nerve to activate the body’s natural Inflammatory Reflex, which is intended to produce a potent systemic anti-inflammatory effect. The company has published positive results from a first-in-human open-label proof-of-concept trial in rheumatoid arthritis in Proceedings of the National Academy of Sciences (PNAS) and presented positive results at the American College of Rheumatology meeting. Current investors in the company include Morgenthaler Ventures, NEA, Topspin Partners, Medtronic, GlaxoSmithKline’s Action Potential Venture Capital Limited and Boston Scientific.

No comments yet.